LIMA, Peru–(BUSINESS WIRE)–Cementos Pacasmayo S.A.A. and subsidiaries (NYSE: CPAC; BVL: CPACASC1) (“the Company” or “Pacasmayo”), a leading cement company serving the Peruvian construction industry, announced today its consolidated results for the third quarter (“3Q26”) and the first nine months of the year (“9M26”). These results have been prepared in accordance with International Financial Reporting Standards (“IFRS”) and are stated in Soles (S/). 3Q26 FINANCIAL AND OPERATIONAL HIGHLIGHTS:
Month: October 2026
Toronto, Oct. 26, 2026 (GLOBE NEWSWIRE) — Faircourt Asset Management Inc., as Manager of the Faircourt Fund (CBOE:FGX), is pleased to announce the monthly distribution payable on the Shares of the below listed Fund.
| Faircourt Funds | Trading Symbol | Distribution Amount (per share/unit) | Ex-Dividend Date | Record Date | Payable Date | |
| Faircourt Gold Income Corp. | FGX | $0.034 | October 29, 2026 | October 30, 2026 | November 13, 2026 | |
Faircourt Asset Management Inc. is the Investment Advisor for Faircourt Gold Income Corp.
This press release is not for distribution in the United States or over United States wire services.
For further information on the Faircourt Funds, please visit www.faircourtassetmgt.com or
please contact 1-800-831-0304.
You will usually pay brokerage fees to your dealer if you purchase or sell Shares of the Fund on the CBOE Canada Exchange or other alternative Canadian trading system (an “exchange”). If the Shares are purchased or sold on an exchange, investors may pay more than the current net asset value when buying Shares of the Fund and may receive less than the current net asset value when selling them.
There are ongoing fees and expenses associated with owning units of an investment fund. An investment fund must prepare disclosure documents that contain key information about the fund. You can find more detailed information about the fund in the public filings available at www.sedar.com. Investment funds are not guaranteed, their values change frequently and past performance may not be repeated.
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited (“Citigroup”) for analysts and investors, to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell lung cancer (“NSCLC”) recently presented at the European Society for Medical Oncology (ESMO) Congress 2026. This virtual webcast will take place on Thursday, November 5, 2026, at 4:30 pm HKT / 8:30 am GMT / 3:30 am EST.
The discussion will be led by Professor Yi-Long Wu, principal investigator of the SANOVO study, who will share insights on the latest clinical data and treatment strategies for MET-driven NSCLC. Dr Weiguo Su, Chief Executive Officer (presently on leave of absence) and Chief Scientific Officer of HUTCHMED, will also join the panel to discuss the development progress to date and global regulatory outlook of savolitinib in light of data from both the SANOVO study in China and the SAFFRON global study. The event will be moderated by Mr Yingqi Peng, Asia Healthcare Research Analyst from Citigroup.
The webcast will be conducted in Chinese (Putonghua) with simultaneous English interpretation. Event and registration details will be available at www.hutch-med.com/event.
About Savolitinib
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor (“TKI”) that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression.
Savolitinib is marketed in China under the brand name ORPATHYS® for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration, representing the first selective MET inhibitor approved in China. Savolitinib also received a conditional approval in China for the treatment of adult patients with locally advanced or metastatic gastric cancer or gastroesophageal junction (GC/GEJ) adenocarcinoma patients with MET amplification who have failed at least two prior systemic treatments. Savolitinib in combination with TAGRISSO® is approved in China for patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-squamous NSCLC with MET amplification after disease progression on EGFR-TKI therapy based on the SACHI Phase III trial. The combination was also granted a temporary authorization in Switzerland for the treatment of patients with locally advanced or metastatic EGFRm NSCLC and high levels of MET overexpression or amplification who progressed on prior treatment with TAGRISSO®. This was based on results from the global SAVANNAH Phase II trial. The global, randomized, SAFFRON Phase III trial in the same treatment setting comparing the combination with doublet platinum-based chemotherapy reported positive high-level results, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival (“PFS”) and overall survival (“OS”) in August 2026.
Savolitinib is being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.
About SANOVO
SANOVO is a blinded, randomized, controlled Phase III trial in previously untreated patients with locally advanced or metastatic NSCLC with activating EGFR mutations and MET overexpression in China conducted by HUTCHMED. The study evaluates the efficacy and safety of savolitinib in combination with TAGRISSO® compared to TAGRISSO® alone, a standard-of-care treatment option for these patients. A total of 326 treatment-naïve patients with locally advanced or metastatic NSCLC harbouring EGFR mutations (exon 19 deletion or L858R) and MET overexpression were randomized in a 1:1 ratio to receive TAGRISSO® 80 mg once daily plus either savolitinib or placebo at 300/200 mg twice daily (dosed based on body weight).
The primary endpoint of the trial is PFS as assessed by investigators. Other endpoints include PFS assessed by an independent review committee, OS, objective response rate, duration of response, disease control rate, time to response and safety.
About SAFFRON
SAFFRON is a randomized, open-label, multi-center, global Phase III trial studying the efficacy of savolitinib (300 mg twice daily) added to TAGRISSO® (80 mg once daily) versus doublet platinum-based chemotherapy in 338 patients with EGFRm, locally advanced or metastatic NSCLC with MET overexpression or amplification whose disease progressed following first- or second-line treatment with TAGRISSO®. The trial enrolled patients in 230 centers across 29 countries in North America, Europe, South America and Asia. The primary endpoint is PFS and key secondary endpoint includes OS.
Patients were prospectively selected for SAFFRON using the high MET level cut-offs identified in the SAVANNAH Phase II trial. In SAVANNAH, MET overexpression or amplification levels were determined by two tests: immunohistochemistry (IHC), which detects if cancer cells have a particular protein or marker on their surface, and fluorescence in situ hybridization (FISH), which detects a specific DNA sequence from cancer cells.
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations regarding the therapeutic potential of savolitinib, the further clinical development for savolitinib, its expectations as to whether any studies on savolitinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of savolitinib, including as a combination therapy, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of savolitinib for a targeted indication; the sufficiency of funding; HUTCHMED’s and AstraZeneca’s ability to successfully develop and commercialize savolitinib. In addition, as certain studies rely on the use of other drug products such as TAGRISSO® as combination therapeutics with savolitinib, such risks and uncertainties include assumptions regarding the safety, efficacy, supply and continued regulatory approval of these therapeutics. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.
Medical Information
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.
CONTACTS
| Investor Enquiries | +852 2121 8200 / ir@hutch-med.com |
| Media Enquiries | |
| FTI Consulting – | +44 20 3727 1030 / HUTCHMED@fticonsulting.com |
| Ben Atwell / Tim Stamper | +44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile) |
| Brunswick – Zhou Yi | +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com |
| Panmure Liberum | Nominated Advisor and Joint Broker |
| Atholl Tweedie / Emma Earl / Rupert Dearden | +44 20 7886 2500 |
| Cavendish | Joint Broker |
| Geoff Nash / Nigel Birks | +44 20 7220 0500 |
| Deutsche Numis | Joint Broker |
| Duncan Monteith / Ramin Naji | +44 20 7545 8000 |
SYDNEY–(BUSINESS WIRE)—- $III #AI–Firms in Asia Pacific are replacing legacy finance and human capital management systems with a Workday platform that improves visibility, ISG says.
FORT WORTH, Texas–(BUSINESS WIRE)–Distribution Solutions Group, Inc. (NASDAQ: DSGR) (“DSG” or the “Company”), a premier specialty distribution company, today announced the successful closing of its previously announced acquisition of GradeEight Holdings, LLC (“GradeEight”), a multi-brand MRO distribution platform operating through a national network of franchisees under Winzer Corporation (“Winzer”), and retail-facing storefronts under FastServ Supply across Texas and Arkansas. The transactio
西班牙马德里–(BUSINESS WIRE)–(美国商业资讯)– 2026年欧洲肿瘤内科学会（ESMO）年会正于西班牙马德里举行。西达本胺（HBI-8000，爱谱沙®）联合纳武利尤单抗治疗晚期黑色素瘤的全球III期临床主要分析结果（摘要编号LBA54）于优选论文报告专场（Proffered Paper Session）进行口头报告。西达本胺其他多项探索成果也同步亮相大会。 专场报告详情 研究标题： Primary Analysis of HBI-8000-303: A Randomized Phase 3 Trial of Nivolumab plus HBI-8000 or Placebo in Advanced Melanoma 中文标题： HBI-8000-303的主要分析：纳武利尤单抗联合HBI-8000或安慰剂治疗晚期黑色素瘤的随机III期试验 摘要编号： LBA54 核心要点 研究背景：在免疫治疗和靶向治疗的推动下，晚期黑色素瘤患者的预后已得到显著改善。在一项针对PD-(L)1抑制剂初治晚期黑色素瘤患者的1b/2期研究中，口服选择性组蛋白去乙酰化酶（HDAC）抑制剂H
SEOUL, South Korea–(BUSINESS WIRE)– #ADC–AimedBio, a clinical-stage biotech company, announces first patient dosed in Phase I trial of ADC candidate BI 4060107.
DUBAI, Vereinigte Arabische Emirate–(BUSINESS WIRE)–Dubai Chambers hat Chamber AI Hub eingeführt, den weltweit ersten digitalen Marktplatz für agentische KI, der von einer Handelskammer initiiert wurde, die Unternehmen in Dubai in die Lage versetzt, Zugang zu einsatzbereiten KI-Agenten zu erhalten, die eine Reihe von administrativen und operativen Aufgaben selbständig übernehmen. Der Marktplatz bietet gegenwärtig 22 spezialisierte KI-Agenten in sieben Geschäftsfunktionen an, einschließlich Co
NEW YORK–(BUSINESS WIRE)–Even Realities, l’azienda ideatrice di occhiali intelligenti senza fotocamera con priorità al display, ha presentato oggi Brown 2, una nuova colorazione di ispirazione al tartarugato per Even G2, assieme a due accessori: Even G2 Clip (polarizzati) e Even G2 Chain. Pensato per portare agli occhiali smart il calore e la personalità degli occhiali tradizionali tartarugati, il modello Brown 2 introduce un materiale di nuovo sviluppo che riproduce il motivo a strati su tut
アラブ首長国連邦、ドバイ–(BUSINESS WIRE)–（ビジネスワイヤ） — ドバイ商工会議所は、商工会議所が開発した世界初となるエージェント型AIマーケットプレイス「Chamber AI Hub」を立ち上げました。これにより、ドバイの企業は多様な管理業務や運営業務を自律的に遂行する、即時利用可能なAIエージェントを利用できるようになります。 同マーケットプレイスでは現在、コンプライアンス、調達、事業運営、財務、営業、人事、および物流の7つの事業機能を対象とした、22種類の特化型AIエージェントを提供しています。今後、その提供数は100種類に拡大される予定です。 今回の取り組みは、民間セクターにおけるエージェント型AIの導入を加速させるというドバイの活動を支援するものであり、企業の業務効率化や競争力強化、事業モデルの変革を促進します。 ドバイ商工会議所の会長であるスルターン・ビン・サイード・アル・マンスーリ氏は、「エージェント型AIへの移行の成否は、技術を導入したかどうかだけで決まるものではありません。企業がこうしたツールをいかに効果的に活用してビジネス上の課題に対処し、具